PL EN


Preferences help
enabled [disable] Abstract
Number of results
2015 | 15 | 4 | 195–201
Article title

Właściwości farmakologiczne i zastosowania kliniczne duloksetyny

Authors
Content
Title variants
EN
Duloxetine: pharmacologic characteristics and clinical use
Languages of publication
EN PL
Abstracts
EN
Duloxetine is a drug from the group of selective serotonin-norepinephrine reuptake inhibitors, with a more balanced profile of pharmacological action on the serotonin transporter and the norepinephrine transporter compared to a commonly used venlafaxine. Its efficacy in the treatment of depressive episodes as well as in the prevention of depression relapse has been well documented in clinical trials. Duloxetine seems to be a particularly interesting therapeutic option for patients with depression and accompanying pain and/or anxiety symptoms. Moreover, its efficacy has been also assessed in elderly population. Apart from depression, duloxetine may also be used in the treatment of generalized anxiety disorder and beyond psychiatry – in the treatment of some pain disorders, painful diabetic neuropathy in particular. Although other indications have also been examined (including fibromyalgia, chronic low back pain, chronic pain related to osteoarthritis and stress incontinence), they have not been registered in Poland. The use of duloxetine does not require any special safety measures, with the exception of patients with alcohol-related liver disease (or any other hepatic damage), patients treated for arterial hypertension and those treated with drugs affecting haemostasis.
PL
Duloksetyna jest lekiem z grupy selektywnych inhibitorów wychwytu zwrotnego serotoniny i noradrenaliny o bardziej zrównoważonym profilu farmakologicznego oddziaływania na transporter serotoninowy i noradrenergiczny niż powszechnie stosowana wenlafaksyna. W badaniach klinicznych udokumentowano jej skuteczność w leczeniu epizodów oraz zapobieganiu nawrotom depresji. Duloksetyna jest szczególnie interesującą opcją terapeutyczną u chorych depresyjnych z towarzyszącymi objawami bólowymi oraz lękowymi, została również przebadana w populacji chorych w wieku podeszłym. Poza leczeniem depresji lek może być stosowany w leczeniu uogólnionego zaburzenia lękowego, a poza psychiatrią także w leczeniu niektórych zaburzeń bólowych, zwłaszcza bolesnej neuropatii cukrzycowej. Choć w badaniach klinicznych weryfikowano kilka innych wskazań (takich jak fibromialgia, przewlekłe bóle pleców, bóle w przebiegu osteoarthritis czy wysiłkowe nietrzymanie moczu), nie mają one w Polsce statusu zarejestrowanych. Stosowanie duloksetyny nie wymaga podejmowania szczególnych środków ostrożności, z wyjątkiem pacjentów z chorobą alkoholową (lub innym uszkodzeniem wątroby), osób leczonych z powodu nadciśnienia tętniczego oraz chorych przyjmujących leki wpływające na hemostazę.
Discipline
Year
Volume
15
Issue
4
Pages
195–201
Physical description
References
  • Alaka KJ, Noble W, Montejo A et al.: Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled trial. Int J Geriatr Psychiatry 2014; 29: 978–986.
  • Arnold LM, Lu Y, Crofford LJ et al.: A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004; 50: 2974–2984.
  • Arnold LM, Rosen A, Pritchett YL et al.: A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005; 119: 5–15.
  • Ball SG, Desaiah D, Zhang Q et al.: Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentary. Drugs Context 2013a; 2013: 212245.
  • Ball S, Marangell LB, Lipsius S et al.: Brain-derived neurotrophic factor in generalized anxiety disorder: results from a duloxetine clinical trial. Prog Neuropsychopharmacol Biol Psychiatry 2013b; 43: 217–221.
  • Basu M, Duckett JR: Update on duloxetine for the management of stress urinary incontinence. Clin Interv Aging 2009; 4: 25–30.
  • Bennett RM: Clinical manifestations and diagnosis of fibromyalgia. Rheumatol Dis Clin North Am 2009; 35: 215–232.
  • Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG et al.: Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001; 25: 871–880.
  • Callaghan BC, Cheng HT, Stables CL et al.: Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol 2012; 11: 521–534.
  • Carville SF, Arendt-Nielsen L, Bliddal H et al.; EULAR: EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008; 67: 536–541.
  • Chappell AS, Bradley LA, Wiltse C et al.: A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. Int J Gen Med 2008; 1: 91–102.
  • Chappell J, He J, Knadler MP et al.: Effects of duloxetine on the pharmacodynamics and pharmacokinetics of warfarin at steady state in healthy subjects. J Clin Pharmacol 2009; 49: 1456–1466.
  • Chen S, Wu N, Fraser K et al.: Opioid use and healthcare costs among patients with DPNP initiating duloxetine versus other treatments. Curr Med Res Opin 2010; 26: 2507–2516.
  • Davidson JR, Wittchen HU, Llorca PM et al.: Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol 2008; 18: 673–681.
  • De Berardis D, Serroni N, Carano A et al.: The role of duloxetine in the treatment of anxiety disorders. Neuropsychiatr Dis Treat 2008; 4: 929–935.
  • Derby MA, Zhang L, Chappell JC et al.: The effects of supratherapeutic doses of duloxetine on blood pressure and pulse rate. J Cardiovasc Pharmacol 2007; 49: 384–393.
  • Dunner DL, Goldstein DJ, Mallinckrodt C et al.: Duloxetine in treatment of anxiety symptoms associated with depression. Depress Anxiety 2003; 18: 53–61.
  • Endicott J, Russell JM, Raskin J et al.: Duloxetine treatment for role functioning improvement in generalized anxiety disorder: three independent studies. J Clin Psychiatry 2007; 68: 518–524.
  • Goldstein DJ, Lu Y, Detke MJ et al.: Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005; 116: 109–118.
  • Hartford J, Kornstein S, Liebowitz M et al.: Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychopharmacol 2007; 22: 167–174.
  • Häuser W, Petzke F, Üçeyler N et al.: Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis. Rheumatology (Oxford) 2011; 50: 532–543.
  • Javed S, Petropoulos IN, Alam U et al.: Treatment of painful diabetic neuropathy. Ther Adv Chronic Dis 2015; 6: 15–28.
  • King JB, Schauerhamer MB, Bellows BK: A review of the clinical utility of duloxetine in the treatment of diabetic peripheral neuropathic pain. Ther Clin Risk Manag 2015; 11: 1163–1175.
  • McIntyre RS, Panjwani ZD, Nguyen HT et al.: The hepatic safety profile of duloxetine: a review. Expert Opin Drug Metab Toxicol 2008; 4: 281–285.
  • Nelson JC, Wohlreich MM, Mallinckrodt CH et al.: Duloxetine for the treatment of major depressive disorder in older patients. Am J Geriatr Psychiatry 2005; 13: 227–235.
  • Nicolini H, Bakish D, Duenas H et al.: Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial. Psychol Med 2009; 39: 267–276.
  • Nierenberg AA, Greist JH, Mallinckrodt CH et al.: Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr Med Res Opin 2007; 23: 401–416.
  • Perahia DG, Gilaberte I, Wang F et al.: Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study. Br J Psychiatry 2006b; 188: 346–353.
  • Perahia DG, Kajdasz DK, Walker DJ et al.: Duloxetine 60 mg once daily in the treatment of milder major depressive disorder. Int J Clin Pract 2006a; 60: 613–620.
  • Perahia DG, Maina G, Thase ME et al.: Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebocontrolled trial. J Clin Psychiatry 2009b; 70: 706–716.
  • Perahia DG, Quail D, Desaiah D et al.: Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: effects on painful physical symptoms of depression. J Psychiatr Res 2009a; 43: 512–518.
  • Raskin J, Pritchett YL, Wang F et al.: A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005; 6: 346–356.
  • Raskin J, Wiltse CG, Siegal A et al.: Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 2007; 164: 900–909.
  • Romera I, Pérez V, Menchón JM et al.: Early vs. conventional switching of antidepressants in patients with MDD and moderate to severe pain: a double-blind randomized study. J Affect Disord 2012; 143: 47–55.
  • Rubio G, López-Ibor JJ: Generalized anxiety disorder: a 40-year follow-up study. Acta Psychiatr Scand 2007; 115: 372–379.
  • Russell IJ, Mease PJ, Smith TR et al.: Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, doubleblind, placebo-controlled, fixed-dose trial. Pain 2008; 136: 432–444.
  • Rynn M, Russell J, Erickson J et al.: Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety 2008; 25: 182–189.
  • Sansone RA, Sansone LA: Serotonin norepinephrine reuptake inhibitors: a pharmacological comparison. Innov Clin Neurosci 2014; 11: 37–42.
  • Schueler YB, Koesters M, Wieseler B et al.: A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. Acta Psychiatr Scand 2011; 123: 247–265.
  • Shelton RC, Prakash A, Mallinckrodt CH et al.: Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression. Int J Clin Pract 2007; 61: 1337–1348.
  • Shelton RC: Serotonin norepinephrine reuptake inhibitors: similarities and differences. Prim Psychiatry 2009; 16 (Suppl 4): 25–35.
  • Signorovitch J, Ramakrishnan K, Ben-Hamadi R et al.: Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors. Curr Med Res Opin 2011; 27: 1089–1096.
  • Spallone V: Management of painful diabetic neuropathy: guideline guidance or jungle? Curr Diab Rep 2012; 12: 403–413.
  • Święcicki Ł: Stosowanie wenlafaksyny w dawkach większych niż 225 mg na dobę. Bilans ryzyka i korzyści. Psychiatr Psychol Klin 2014; 14: 213–217.
  • Wernicke JF, Pritchett YL, D’Souza DN et al.: A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006; 67: 1411–1420.
  • Wolfe F, Clauw DJ, Fitzcharles MA et al.: The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010; 62: 600–610.
  • Wu N, Chen SY, Hallett LA et al.: Opioid utilization and health-care costs among patients with diabetic peripheral neuropathic pain treated with duloxetine vs. other therapies. Pain Pract 2011; 11: 48–56.
  • Wysokiński A, Margulska A, Sobow T: Bleeding complications in the course of treatment with antidepressants in elderly patients. Curr Psychiatry Rev 2015; 11: 244–249.
Document Type
review
Publication order reference
YADDA identifier
bwmeta1.element.psjd-4d32bed5-52c7-4feb-ba97-114215895853
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.